Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

17/433 Matches for
“direct-acting antiviral agents”

“direct-acting antiviral agents” Clear all

  1. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.

    Asselah T et al. · Liver Int · 2018 Match 100

    ### Background & Aims Patients with chronic hepatitis C virus infection and advanced fibrosis…

    FibroTest HCV

  2. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.

    Preda CM et al. · Liver Int · 2018 Match 98

    ### Background Direct antiviral agents (DAA) showed very good results in terms of…

    FibroTest HCV

  3. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.

    Steininger K et al. · J Viral Hepat · 2017 Match 95

    …New direct-acting antiviral agent (DAA) combination therapy has not yet been…

    FibroTest HCV HIV

  4. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

    Afdhal NH et al. · J Viral Hepat · 2013 Match 92

    Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…

    ActiTest FibroTest HCV

  5. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 89

    ### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…

    ActiTest FibroTest Alcohol HBV +3

  6. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.

    Akuta N et al. · J Gastroenterol · 2018 Match 86

    ### Background In the UNITY-3 study, 96% sustained virologic response (SVR12) rate…

    FibroTest HCV

  7. Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.

    Haseltine EL et al. · J Viral Hepat · 2015 Match 83

    …successful treatment with telaprevir-based antiviral regimens. We performed a retrospective analysis…

    FibroTest HCV

  8. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Match 80

    ActiTest FibroTest HCV

  9. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Match 77

    …Specifically, direct-acting antiviral agents with dramatically improved rates of virological clearance…

    FibroTest HCV

  10. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Match 74

    ActiTest FibroTest HCV

  11. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

    Poynard T et al. · JHEP Rep · 2021 Match 71

    ### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…

    LCR1 LCR2 HCV

  12. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.

    Poynard T et al. · Antivir Ther · 2010 Match 68

    ### Background Liver biopsy and virological end points are standard references for assessing…

    ActiTest FibroTest HBV HCV +1

  13. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Match 65

    ActiTest FibroTest HBV

  14. Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication

    Match 62

    FibroTest HCV

  15. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 59

    FibroTest Alcohol HBV HCV +3

  16. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 56

    FibroTest HBV

  17. Ministère des Affaires Sociales et de la Santé Key publication

    Match 53

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.